Construction of west nile virus and dengue virus chimeras for use in a live virus vaccine to prevent disease caused by west nile virus

Patent metadata

Field	Value
Publication number	US-2021069317-A1
Application number	US-202016952864-A
Country	US
Kind code	A1
Filing date	Nov 19, 2020
Priority date	Jan 10, 2002
Publication date	Mar 11, 2021
Grant date	—

Abstract

The present invention relates to attenuated, immunogenic West Nile virus chimeras built on a dengue virus backbone for the production of immunogenic, live, attenuated West Nile virus vaccines,

First claim

1 - 27 . (canceled)

28 . A method of inducing an immune response in a subject, comprising administering to the subject an immunogenic composition comprising about 100 to about 100,000 PFU of a virus chimera comprising a first nucleotide sequence encoding a premembrane/membrane (prM) protein and an envelope (E) protein from a West Nile virus, and a second nucleotide sequence encoding a capsid (C) protein and nonstructural proteins from a dengue type 4 virus and the 3′ untranslated region of the dengue type 4 genome comprising a deletion of about 30 nucleotides between nucleotides 10478-10507 corresponding to the TL2 stem-loop structure.

29 . The method of claim 28 , wherein the method comprises administering the immunogenic composition to the subject subcutaneously.

30 . The method of claim 28 , wherein the method comprises administering one to five doses of the immunogenic composition to the subject.

31 . The method of claim 28 , wherein the subject is a human.

32 . The method of claim 28 , wherein the subject is a non-human primate.

33 . The method of claim 28 , wherein the subject is a bird or a horse.

34 . The method of claim 28 , wherein the immunogenic composition further comprises an adjuvant.

35 . The method of claim 28 , wherein the West Nile virus is strain NY99.

36 . The method of claim 28 , wherein the virus chimera comprises a cleavage site joining the dengue virus capsid protein and the West Nile virus prM protein, and wherein the West Nile virus prM protein contains aspartic acid (Asp)at a position 3 amino acids downstream of the cleavage site and contains threonine (Thr) at a position 6 amino acids downstream of the cleavage site, wherein the cleavage site corresponds to amino acid position 3 of SEQ ID NO: 3.

Assignees

• Us Health
• Us Gov Sec Army

Inventors

• Pletnev Alexander G
• Putnak Joseph R
• Chanock Robert M
• Murphy Brian R
• Whitehead Stephen S
• Blaney Joseph E

Classifications

• Y02A50/30

  Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change · CPC title

• C12N15/86

  Viral vectors · CPC title

• A61K39/12 Primary

  Viral antigens · CPC title

• A61P31/14

  for RNA viruses · CPC title

• C12N2770/24134

  Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title